**UMOEN Oncology Journal Club**

**May 2022**

ZYNLONTA (loncastuximab tesirine-lpyl), the First-and-Only CD19-Targeted ADC, for the Treatment of Adults with R/R DLBCL After Two or More Lines of Systemic Therapy by Anand Tandra, MD, Indiana Blood and Marrow Transplant

Updates in the Treatment of Multiple Myeloma by Kirollos Hanna, PharmD, BCOP, BCPS, Oncology Pharmacy Manager, M Health Fairview Maple Grove Cancer Center

Tebentafusp for Unresectable or Metastatic Uveal Melanoma: A New Drug Discussion by Ian Watson, PharmD, PGY-2 Oncology Pharmacy Resident, M Health Fairview